**This webpage was produced as an assignment for an undergraduate course at Davidson College**



Aurelian L.  Herpes simplex virus type 2 vaccines: new ground for optimism? Clinical and Diagnostic Laboratory Immunology 2004; 11(30): 437-445.

Aoki FY, Tyring S, Diaz-Mitoma F, et al.  Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006; 42: 8-13.

Braun RP, Payne LG, Dong L.  Characterization of the IFN-γ T cell responses to immediate early antigens in humans with genital herpes.  Virology Journal 2006; 3:54.

Bystricka M and Russ G.  Immunity in latent herpes simplex virus infection.  Acta virologica  2005; 49: 159-167.

Cunningham AL, Diefenbach RJ, Miranda-Saksena M, Bosnjak L, Kim M, Jones C, Douglas MW. The cycle of human herpes simplex virus infection: virus transport and immune control.  J Infect Dis 2006; 194(Suppl 1): S11-8.

Da Costa, XJ, Brockman MA, Alicot, E et al.  Humoral response to herpes simplex virus is complement-dependent.  PNAS 1999; 96(22): 12708-12712.

Dohner K, Wolfstein A, Prank U, Echeverri C, Dujardin D, Vallee R, Sodeik B. Function of dynein and dynactin in herpes simplex virus capsid transport. Mol Biol Cell. 2002; 13(8):2795-809

Friedman HM.  Immune evasion by herpes simplex virus type 1, strategies for virus survival.  Trans Am Clin Climatol Assoc. 2003; 114: 103-112.

Gesser RM, Valyi-Nagy T, Fraser NW. Restricted herpes simplex virus type 1 gene expression within sensory neurons in the absence of functional B and T lymphocytes. Virology 1994; 200(2): 791-5.

Ghaemi A, Soleimanjahi H, Bamdad T, Soudi S, Arefeian E, Hashemi SM, Ebtekar M.  Induction of humoral and cellular immunity against latent HSV-1 infections by DNA immunization in BALB/c mice. Comp Immunol Microbiol Infect Dis. 2007. (epub ahead of print).

Herbst-Kralovetz, MM and Pyles, RB.  Toll-like receptors, innate immunity and HSV pathogenesis.  Herpes 2006; 13(2): 37-41.

Herold BC, WuDunn D, Soltys N, Spear PG. Glycoprotein C of herpes simplex virus type 1 plays a principle role in the adsorption of virus to cells and in infectivity.  J Virol. 1991; 65: 1090-1098.

Hill A, Jugovic P, York I et al.  Herpes simplex virus turns off the TAP to evade host immunity. Nature 1995; 375(6530): 411-5.

Janeway, C.  Immunobiology.  6th edition.  New York: Garland Science Publishing, 2005.
Jenkins FJ and Turner SL.  Herpes simplex virus: a tool for neuroscientists.  Frontiers in Bioscience 1996; 1: d241-247.

Johnson DC, Frame MC, Ligas MW et al.  Herpes simplex virus immunoglobulin G Fc receptor activity depends on a complex of two viral glycoproteins, gE and gI.  J Virol. 1988; 62(4): 1347-54.

Khanna KM, Bonneau RH, Kinchington PR, Hendricks RL.  Herpes simplex virus-specific memory CD8+ T cells are selectively activated and retained in latently infected sensory ganglia. Immunity 2003;18(5): 593-603.

Khanna KM, Lepisto AJ, Decman V, Hendricks RL.  Immune control of herpes simplex virus during latency.  Current Opinion in Immunology 2004; 16: 463-469.

Koelle DM, Posavad CM, Barnum GR et al.  Clearance of HSV-2 from recurrent genital lesions correlates with infiltration of HSV-specific cytotoxic T lymphocytes. J Clin Invest. 1998; 101(7): 1500-8.

Mikloska Z, Kesson AM, Penfold ME, Cunningham AL. Herpes simplex virus protein targets for CD4 and CD8 lymphocyte cytotoxicity in cultured epidermal keratinocytes treated with interferon-gamma.  J Infect Dis. 1996;173(1):7-17.

Mikloska Z, Sanna PP, Cunningham AL.  Neutralizing antibodies inhibit axonal spread of herpes simplex virus type 1 to epidermal cells in vitro. J Virol. 1999; 73(7): 5934-44.

Minagawa H and Yanagi Y.  Latent herpes simplex virus-1 infection in SCID mice transferred with immune CD4+T cells: a new model for latency. Arch Virol. 2000; 145(11): 2259-72.

Rajcani J and Durmanova V.  Developments in herpes simplex virus vaccines: old problems and new challenges.  Folia Microbiol. 2006; 51(2): 67-85.

Schang LM, St Vincent MR, Lacasse JJ.  Five years of progress on cyclin-dependent kinases and other cellular proteins as potential targets for antiviral drugs.  Antivir Chem Chemother. 2006; 17(6): 293-320.

Seidel-Dugan C, Ponce de Leon M, Friedman HM, et al.  C3b receptor activity on transfected cells expressing glycoprotein C of herpes simplex virus types 1 and 2.  J Virol 1988; 62(11): 4027-4036.

Smiley, JR.  Herpes simplex virus virion host shutoff protein: immune evasion mediated by a viral RNase?  J Virol. 2004; 78(3): 1063-1068.

Spear PG.  Herpes simplex virus: receptors and ligands for cell entry.  Cell Microbiol.  2004; 6(5): 401-10.

Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, Tyring S, Aoki FY, Slaoui M, Denis M, Vandepapeliere P, Dubin G; GlaxoSmithKline Herpes Vaccine Efficacy Study Group. Glycoprotein-D-adjuvant vaccine to prevent genital herpes.  N Engl J Med. 2002 Nov 21;347(21):1652-61

Trgovcich J, Johnson D, Roizman B.  Cell surface major histocompatibility complex class II proteins are regulated by the products of the gamma134.5 and UL41 genes of herpes simplex virus 1.  J Virol. 2002; 76: 6974-6986.

Whitley RJ, Miller RL.  Immunologic approach to herpes simplex virus.  Viral Immunol. 2001;14(2):111-8.


Back to Home Page


Davidson College Biology Department

Contact jehodge@davidson.edu with questions or comments.